Patient, consumer groups push back on biologics exclusivity

A group of 28 patient, consumer, labor, insurance and other organizations urged the Trump administration to reconsider the proposed 10-year brand-name biologic exclusivity provision in the U.S.-Mexico-Canada Agreement (USMCA).